UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER
kmUU300MXic
kmUU300MXic
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Presentations<br />
Metastatic melanoma, glioblastoma and high-grade extrapulmonary<br />
neuroendocrine carcinomas (NECs) as novel indications for<br />
rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted<br />
antibody-drug conjugate (ADC).<br />
Authors*: Stanford L. Peng, Laura Saunders, Sheila Bheddah, Sam Williams, Rahul Raj Aggarwal,<br />
Jill E. Shea, Eun Y Lee, Jiaoti Huang, Allison J Zemek, Teri A. Longacre, Douglas Wilmot Ball,<br />
Courtney L. Scaife, Barry Nelkin, Lowell Brian Anthony, Pamela L. Kunz, Eric Jay Small, Scott Dylla<br />
Abstract #: 11611<br />
Presentation Date/Time: Monday, June 6: 1:00 - 4:30 PM<br />
Location: Hall A, Poster Board #308<br />
Poster Session: Tumor Biology<br />
Citation: J Clin Oncol 34, 2016 (suppl; abstr 11611)<br />
Small Research Interests: The Stand Up To Cancer Dream Team led by Dr. Eric Small is exploring the idea<br />
that resistance to hormonal therapy occurs as a result of the prostate cancer cells using common cellular<br />
responses - what the Dream Team calls “adaptive pathways” - to escape the current prostate cancer<br />
therapies. They believe that, by identifying these pathways and inhibiting them, they will be able to overcome<br />
treatment resistance and profoundly improve the care of men affected by this fatal disease. This team is a six<br />
institution consortium to include UC Los Angeles, UC Davis, UC Santa Cruz, University of British Columbia,<br />
Oregon Health and Sciences University, with <strong>UCSF</strong> as the lead administrative site.<br />
http://cancer.ucsf.edu/people/profiles/small_eric.3671<br />
*<strong>UCSF</strong> authors in bold<br />
83
Change language